Yokohama, Japan · Founded 2019 · Privately Held (backing)
Operator of a biopharmaceutical company intended to develop therapeutic monoclonal antibody drugs for humans and animals. MabGenesis is based in Yokohama, Japan and was founded in 2019. Its last reported valuation was $18.6 million in Dec 2024. It has raised $8.8 million.
Last reported valuation
$18.6M
Oct 2026
Priced at
—
Total raised
$8.8M
Last round
—
Cap table — not yet on record
MabGenesis's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of MabGenesis with a free account
·Watch MabGenesis: the Monday email on marks, rounds and moves
